Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Perinatal Outcomes in Pregnancies Managed with Antenatal Insulin Glargine

Egerman, Robert, Ramsey, Risa, Kao, Lu, Bringman, Jay, Haerian, Haleh, Kao, Jerome, Bush, Andrew · 2009 · American Journal of Perinatology

Abstract

We compared perinatal outcomes in pregnancies in which insulin glargine was used in the management of patients with pregnancies in which standard insulin therapy was used at a single institution. A retrospective analysis of 114 pregnant patients with diabetes (pregestational or gestational) managed at a single center between January 2004 and August 2006 was undertaken. Sixty-five patients managed with insulin glargine were compared with 49 patients managed with neutral protamine Hagedorn (NPH) insulin. Both groups were also treated with short-acting insulin (either regular, lispro, or aspart insulin). Maternal age, parity, prepregnancy weight, body mass index, duration of diabetes, hemoglobin A (1C) (at entry and final recorded) and gestational age at entry were similar for each group (glargine and NPH). Thirty patients had gestational diabetes (18 glargine and 12 NPH); there were no differences in numbers of patients in higher-order White's classification between the two groups. Cesarean section for obstetric reasons included labor abnormalities, malpresentation, fetal distress, and suspected macrosomia. There were no differences in gestational age at delivery, birth weight, preeclampsia, or frequency of cesarean section (total or for obstetric reasons). The frequency of shoulder dystocia was higher in the NPH group. Regarding neonatal outcomes, gestational age at delivery, birth weight, Apgar scores, admission to the neonatal intensive care unit, respiratory distress syndrome, hypoglycemia, and congenital anomalies were similar between the two groups. From this retrospective analysis, no adverse maternal or neonatal effects were seen from maternal administration of insulin glargine. A larger multicenter study is needed to confirm these findings. This preliminary report suggests that use of insulin glargine during pregnancy can be considered if maternal metabolic control is suboptimal using the standard split-mix regimen.

Overview

Integrity signals

Registry

Crossref · 10.1055/s-0029-1220782

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

Cited by 35

Metadata

Authors
Egerman, R., Ramsey, R., Kao, L., Bringman, J., Haerian, H., Kao, J., & Bush, A.
Affiliations
  • West Virginia University (US)
  • University of Tennessee Health Science Center (US)
Venue
American Journal of Perinatology
Published
2009-04-15
Volume
26
Issue
08
Pages
591-595
ISSN
  • 0735-1631 (ISSN-L)
  • 1098-8785
OpenAlex
W2051504119
Cited by
35
References
0
Citations by year
2022: 1 · 2021: 2 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 4 · 2014: 1 · 2013: 3 · 2012: 3
FWCI
5.36
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Perinatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
insulin glargine, perinatal outcomes, gestational diabetes mellitus, pregestational diabetes, NPH insulin, cesarean section, shoulder dystocia, neonatal outcomes, maternal glycemic control, congenital malformations
MeSH terms
Insulin Glargine, Adult, Female, Humans, Hypoglycemic Agents, Infant, Newborn, Insulin, Insulin, Isophane, Pregnancy, Pregnancy in Diabetics, Pregnancy Outcome, Diabetes, Gestational, Insulin, Long-Acting, Insulin Aspart, Insulin Lispro

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Perinatal Outcomes in Pregnancies Managed with Antenatal Insulin Glargine. https://app.cochat.ai/papers/10.1055/s-0029-1220782
The paper
Egerman, R., Ramsey, R., Kao, L., Bringman, J., Haerian, H., Kao, J., & Bush, A. (2009). Perinatal Outcomes in Pregnancies Managed with Antenatal Insulin Glargine. American Journal of Perinatology. https://doi.org/10.1055/s-0029-1220782

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.